Nintenderos15d
Kero Quest 64, un homenaje a Nintendo 64, llegará a Nintendo Switch y tal vez a Nintendo Switch 2
Una noticia que encantará a los fans de Nintendo 64. En concreto, parece que hay un nuevo tributo que podría llegar a Nintendo Switch ...
Investing6d
Piper Sandler reduce el objetivo de precio de las acciones de Keros a 15 dólares, mantiene la calificación de Sobreponderar
El viernes, Piper Sandler ajustó sus perspectivas sobre Keros Therapeutics (NASDAQ:KROS), reduciendo significativamente el precio objetivo de 40,00 dólares a 15,00 dólares, mientras mantiene ...
Investing8d
Recorte del precio objetivo de las acciones de Keros tras la terminación del estudio
El jueves, Oppenheimer ajustó su precio objetivo para las acciones de Keros Therapeutics (NASDAQ:KROS), reduciéndolo significativamente a 23,00 dólares desde el objetivo anterior de 63,00 ...
FierceBiotech9d
Keros, after halting 2 cohorts over fluid buildups around heart, pulls plug on hypertension trial
A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension drug, Keros Therapeutics has now pulled the plug on the study entirely.
Business Insider8d
Keros Therapeutics: Buy Rating Affirmed Despite Setbacks, Driven by Strong Pipeline and Strategic Partnerships
Analyst Jason Zemansky of Bank of America Securities reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), reducing the price target to $32.00. Discover outperforming stocks ...
Business Insider9d
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical ...
pharmaphorum9d
Keros pulls study of Winrevair rival after safety signal
Keros Therapeutics has abandoned a phase 2 trial of its drug candidate for pulmonary arterial hypertension (PAH), cibotacept, after seeing evidence of potentially serious cardiovascular side effects.
Yahoo Finance9d
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...
Nasdaq7d
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)
During the last three months, 11 analysts shared their evaluations of Keros Therapeutics (NASDAQ:KROS), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a ...
ETF Daily News29d
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 2.7% on Analyst Downgrade
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) traded down 2.7% during trading on Tuesday after Truist Financial lowered their price target on the stock from $100.00 to $43.00.
health.economictimes.indiatimes8d
Keros halts blood pressure treatment trial on safety issues
Bengaluru: Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage trial, causing its shares to ...